Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The MRC Anatomical Neuropharmacology Unit at the University of Oxford (MRC ANU) closed on the 31 March after 30 years of world leading research on the complex networks of the brain. Under the leadership of director Professor Peter Somogyi and associate director Professor Paul Bolam, the MRC ANU has played a vital role in understanding healthy brain function and disorders such as Parkinson's disease.

From 1 April, the ANU will transition to become a new university unit, the MRC Brain Network Dynamics Unit at the University of Oxford (MRC BNDU), located on the same site in the Department of Pharmacology. The new Unit, led by director Professor Peter Brown, will build on the success of the MRC ANU and use animal models and patients to understand brain circuitry in some of the most prevalent and debilitating brain disorders such as Parkinson’s disease, memory disorders and Alzheimer’s disease. The MRC BNDU will be uniquely multidisciplinary and integrate research programmes covering clinical, experimental and computational neuroscience in both the Department of Pharmacology and the Nuffield Department of Clinical Neurosciences.

Sir John Savill - MRC Chief Executive said "The MRC Anatomical Neuropharmacology Unit has been fundamental in advancing our understanding of brain connections and what happens when these connections are disrupted. It has established an internationally respected record of research and an impressive portfolio of achievements upon which we now hope to build through the new MRC Brain Network Dynamics Unit"

Our collective goal is to understand and exploit the moment-to-moment interactions between nerve cells that are critical for brain functions, with a special focus on the brain circuits underlying movement and memory. In achieving this, we aim to develop and deliver novel therapies that specifically target the disturbed circuit interactions arising in disease.
Professor Peter Brown